Plain-English translation of NCT07144280 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works better than the standard chemotherapy drug docetaxel for people with advanced non-small cell lung cancer that has stopped responding to previous treatments. The medication is designed to target cancer cells by blocking a protein called PD-L1. Researchers want to see if this new approach helps people live longer and feel better than the current standard treatment.
Many people with advanced lung cancer eventually stop responding to their initial treatments, and doctors need better options to help them. This medication is being tested because it may work through a different mechanism than treatments patients have already received, potentially offering hope when other therapies no longer work.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or the standard chemotherapy. If you receive the new medication, you'll get intravenous infusions (shots into your veins) twice every 21 days; if you receive the standard treatment, you'll get one infusion every 21 days. You'll have regular clinic visits to check how you're responding, and you may continue in the study for up to 5 years if the treatment is working for you.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States